Human metapneumovirus M2-2 protein inhibits RIG-I signaling by preventing TRIM25-mediated RIG-I ubiquitination. 2022

Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Retinoic acid-inducible gene I (RIG-I) is a receptor that senses viral RNA and interacts with mitochondrial antiviral signaling (MAVS) protein, leading to the production of type I interferons and inflammatory cytokines to establish an antiviral state. This signaling axis is initiated by the K63-linked RIG-I ubiquitination, mediated by E3 ubiquitin ligases such as TRIM25. However, many viruses, including several members of the family Paramyxoviridae and human respiratory syncytial virus (HRSV), a member of the family Pneumoviridae, escape the immune system by targeting RIG-I/TRIM25 signaling. In this study, we screened human metapneumovirus (HMPV) open reading frames (ORFs) for their ability to block RIG-I signaling reconstituted in HEK293T cells by transfection with TRIM25 and RIG-I CARD (an N-terminal CARD domain that is constitutively active in RIG-I signaling). HMPV M2-2 was the most potent inhibitor of RIG-I/TRIM25-mediated interferon (IFN)-β activation. M2-2 silencing induced the activation of transcription factors (IRF and NF-kB) downstream of RIG-I signaling in A549 cells. Moreover, M2-2 inhibited RIG-I ubiquitination and CARD-dependent interactions with MAVS. Immunoprecipitation revealed that M2-2 forms a stable complex with RIG-I CARD/TRIM25 via direct interaction with the SPRY domain of TRIM25. Similarly, HRSV NS1 also formed a stable complex with RIG-I CARD/TRIM25 and inhibited RIG-I ubiquitination. Notably, the inhibitory actions of HMPV M2-2 and HRSV NS1 are similar to those of V proteins of several members of the Paramyxoviridae family. In this study, we have identified a novel mechanism of immune escape by HMPV, similar to that of Pneumoviridae and Paramyxoviridae family members.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D010252 Paramyxoviridae A family of spherical viruses, of the order MONONEGAVIRALES, somewhat larger than the orthomyxoviruses, and containing single-stranded RNA. Subfamilies include PARAMYXOVIRINAE and PNEUMOVIRINAE. Ferlavirus,Ferlaviruses
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070584 Tripartite Motif Proteins A protein family defined by the presence of three ZINC FINGER domains, one of which is a RING FINGER DOMAIN, a coiled-coil region, and a highly variable C-terminal region. They function in many cellular processes including APOPTOSIS and CELL CYCLE regulation. RBCC Protein,TRIM Protein,Tripartite Motif Protein,RBCC Protein Family,RBCC Proteins,TRIM Protein Family,TRIM Proteins,Family, RBCC Protein,Family, TRIM Protein,Motif Protein, Tripartite,Motif Proteins, Tripartite,Protein Family, RBCC,Protein Family, TRIM,Protein, RBCC,Protein, TRIM,Protein, Tripartite Motif,Proteins, RBCC,Proteins, TRIM,Proteins, Tripartite Motif
D000071457 DEAD Box Protein 58 A DEAD-box RNA helicase that contains an N-terminal DEATH-LIKE DOMAIN, AAA+ ATPase domain, and C-terminal RNA HELICASE activity. It functions as an innate immune receptor through its recognition of viral nucleic acids. It also induces the expression of INTERFERON TYPE I and proinflammatory CYTOKINES. Its ligands include: 5'-triphosphorylated SINGLE-STRANDED RNA, DOUBLE-STRANDED RNA (dsRNA), and short dsRNA (less than 1 kb in length). DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 58,Probable ATP-Dependent RNA Helicase DDX58,RIG-I-like Receptor 1,Probable ATP Dependent RNA Helicase DDX58,RIG I like Receptor 1
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D016899 Interferon-beta One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Interferon, Fibroblast,beta-Interferon,Fiblaferon,Interferon, beta,Interferon, beta-1,Interferon-beta1,beta-1 Interferon,Fibroblast Interferon,Interferon beta,Interferon beta1,Interferon, beta 1,beta 1 Interferon,beta Interferon

Related Publications

Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
November 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
December 2018, Viruses,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
December 2012, Journal of virology,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
October 2018, Cellular immunology,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
April 2017, Journal of virology,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
October 2019, Molecules and cells,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
July 2021, eLife,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
February 2020, Viruses,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
June 2019, Veterinary microbiology,
Yukie Tanaka, and Naoko Morita, and Yoshinori Kitagawa, and Bin Gotoh, and Takayuki Komatsu
September 2021, eLife,
Copied contents to your clipboard!